Ardent Health Partners, Inc. (ARDT) AI Stock Analysis

• Market Cap: $1.79B
• Dividend Yield: N/A
• Average Volume (3M): 480.32K
• Price to Earnings (P/E): 7.0
• Beta (1Y): 0.49
• Revenue Growth: 10.03%
• EPS Growth: 197.26%
• Country: US
• Employees: 19,200
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Care Facilities
• EPS (TTM): 0.52
• Shares Outstanding: 143,106,450
• 10 Day Avg. Volume: 500,939
• 30 Day Avg. Volume: 480,316
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.27
• Enterprise Value/Revenue: 0.65
• Enterprise Value/Gross Profit: 1.07
• Enterprise Value/Ebitda: 6.90
• 1Y Price Target: $18.17
• Price Target Upside: 45.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 66 Neutral
• Price Target: $12.00 ▼(-3.92% Downside)

Ardent Health Partners, Inc. demonstrates strong financial performance and a favorable valuation, contributing positively to the overall score. The earnings call provided additional confidence with strategic growth initiatives and operational improvements. However, technical analysis indicates bearish momentum, which tempers the overall score.

Positive Factors

Earnings

ARDT reported 2Q earnings well ahead of estimates, with the extent of the beat largely contingent on NM DPP program approval, which provided a significant EBITDA benefit.

Market Positioning

ARDT's market positioning is considered structurally attractive compared to the national average, driving volume, demand, and pricing growth in line with or above peers.

Negative Factors

Medicaid Cuts

Increasing headwinds from cuts to Medicaid and Accountable Care Act (ACA) exchanges are expected to lower volume growth and increase bad debt.

Regulatory Risks

ARDT should trade at a discount to publicly traded hospital peers due to its smaller scale, lower-margin profile, greater execution risk in ambulatory, and potential regulatory risks.

Ardent Health Partners, Inc. Business Overview & Revenue Model

Company Description

Ardent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.

How the Company Makes Money

Ardent Health Partners generates revenue primarily through the provision of healthcare services, which include inpatient and outpatient care, surgical services, emergency services, and rehabilitation services. The company's revenue model is largely based on reimbursements from government programs such as Medicare and Medicaid, as well as private insurance payers. Key revenue streams include patient services revenue, which accounts for the majority of its income, and ancillary services like laboratory and imaging services, which provide additional financial support. Ardent Health also engages in strategic partnerships with other healthcare organizations and participates in value-based care initiatives that can lead to shared savings and improved reimbursement rates. These factors, combined with a focus on operational efficiency and patient satisfaction, contribute to the company's overall financial performance.

Ardent Health Partners, Inc. Financial Statement Overview

Summary

Ardent Health Partners, Inc. exhibits strong revenue growth and improved profitability, supported by a stable balance sheet and robust cash flow generation. While the company shows effective cost management and shareholder returns, there are areas for improvement in operational efficiency and liquidity management. The reliance on debt financing poses a potential risk, but the company maintains a solid financial position in the medical care facilities industry.

Income Statement

Ardent Health Partners, Inc. has shown strong revenue growth with a 10.29% increase from 2023 to 2024. The gross profit margin is robust at 57.51% for 2024, indicating effective cost management. The net profit margin improved significantly to 3.53% in 2024 from 0.93% in 2023, reflecting enhanced profitability. However, the EBIT and EBITDA margins, at 6.80% and 9.32% respectively, suggest room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 1.50, indicating a balanced approach to leveraging. Return on equity improved to 13.83% in 2024, showcasing effective use of shareholder funds. The equity ratio stands at 30.69%, which is reasonable but suggests a reliance on debt financing. Overall, the balance sheet reflects stability with potential risks from leverage.

Cash Flow

Ardent Health Partners, Inc. has demonstrated a positive free cash flow growth rate of 51.26% from 2023 to 2024, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.50, suggesting efficient cash conversion. However, the free cash flow to net income ratio is 0.61, indicating that not all net income is translating into free cash flow, which could be a concern for liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2018	Dec 2017
Income Statement
Total Revenue	6.20B	5.97B	5.41B	5.13B	4.16B	3.00B
Gross Profit	3.79B	3.43B	4.42B	4.17B	4.16B	3.00B
EBITDA	586.78M	555.92M	350.00M	531.70M	281.84M	230.91M
Net Income	254.86M	210.34M	50.29M	188.91M	-143.02M	-35.65M
Balance Sheet
Total Assets	5.03B	4.96B	4.73B	4.86B	2.75B	2.37B
Cash, Cash Equivalents and Short-Term Investments	540.63M	556.78M	437.58M	456.12M	59.66M	71.96M
Total Debt	2.27B	2.28B	2.40B	2.39B	1.26B	952.69M
Total Liabilities	3.38B	3.43B	3.65B	3.81B	2.03B	1.61B
Stockholders Equity	1.25B	1.52B	670.90M	639.05M	331.64M	377.72M
Cash Flow
Free Cash Flow	36.84M	127.52M	84.29M	-189.47M	-1.07M	-2.06M
Operating Cash Flow	184.49M	315.03M	221.70M	-38.36M	159.59M	119.47M
Investing Cash Flow	-173.07M	-220.46M	-137.98M	46.58M	-525.11M	-983.27M
Financing Cash Flow	149.09M	24.64M	-102.26M	-270.33M	353.22M	843.15M

Ardent Health Partners, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Neutral. The current price of 12.49 is above the 20-day moving average (MA) of 11.18, below the 50-day MA of 12.57, and below the 200-day MA of 14.34, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 90.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARDT.

Ardent Health Partners, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADUS	78 Outperform	$2.10B	25.11	8.54%	―	14.29%	7.85%
ASTH	72 Outperform	$1.47B	57.23	3.50%	―	51.97%	-64.10%
SEM	71 Outperform	$1.56B	11.81	8.15%	2.02%	-16.10%	-48.97%
ACHC	70 Outperform	$1.91B	13.61	4.62%	―	5.64%	―
ARDT	66 Neutral	$1.79B	6.96	25.56%	―	10.03%	197.26%
Sector *	65 Neutral	¥341.81B	11.08	-0.17%	2.40%	9.51%	-9.51%
AGL	39 Underperform	$439.29M	―	-60.64%	―	10.12%	-29.12%

Ardent Health Partners, Inc. Corporate Events

Ardent Health Announces Departure of Hospital Operations President

On June 16, 2025, Ardent Health, Inc. announced the immediate departure of David Schultz from his role as President of Hospital Operations. His exit is classified as a ‘Qualifying Termination’ under the company’s Executive Severance Plan, entitling him to severance benefits as outlined in the company’s proxy statement and previous filings.

The most recent analyst rating on (ARDT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Ardent Health Partners, Inc. stock, see the ARDT Stock Forecast page.

Ardent Health Partners Announces Name Change to Ardent Health

On May 22, 2025, Ardent Health Partners, Inc. announced a name change to Ardent Health, Inc., effective June 3, 2025, with the amendment approved by the Board of Directors and not requiring stockholder approval. The company’s stock will continue trading under the symbol ‘ARDT’ on the New York Stock Exchange. At the Annual Meeting of Stockholders on May 21, 2025, 11 directors were elected, executive compensation was approved on a non-binding basis, and Ernst & Young LLP was ratified as the independent accounting firm for 2025.

The most recent analyst rating on (ARDT) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Ardent Health Partners, Inc. stock, see the ARDT Stock Forecast page.